Objective: The objective of this study was to analyze the effectiveness and long-term tolerability of adjuvant lacosamide (LCM) in a multicenter cohort. We aim to assess outcomes of LCM-containing antiepileptic drug (AED) combinations based upon 'mechanism of action' (MoA) and patient's clinical features. Methods: Consecutive patients commenced on LCM, with focal epilepsy were identified from three Australian hospitals. The 12-month efficacy endpoints were greater than 50% reduction in seizure frequency (responders) and seizure freedom. Tolerability endpoints were cessation of LCM for any reason, cessation due to side-effects and censoring due to inefficacy. Outcomes were assessed according to concomitant AEDs according to their MoA and the clinical risk factor profile. Results: Three hundred ten patients were analyzed and followed for median 17.3 months. Two hundred ninetynine (97%) had drug-resistant epilepsy, and 155 (50%) had tried more than 7 AEDs at LCM commencement. Adjuvant LCM was associated with responder and seizure freedom rate of 29% and 9% respectively at 12 months. Lower baseline seizure frequency, a prior 6-month period of seizure freedom at any time since epilepsy diagnosis and being on fewer concomitant AEDs were predictive of 12-month seizure freedom. Previous focal to bilateral tonic-clonic seizures (FBTCS), lower baseline seizure frequency, and concomitant AED reduction after LCM commencement were associated with improved LCM tolerability. No specific MoA AED combinations offered any efficacy or tolerability advantage. Significance: Adjuvant LCM is associated with seizure freedom rates of 9% at 12 months after commencement and is predicted by lower prior seizure frequency, a period of 6 months or longer of seizure freedom since diagnosis and fewer concomitant AEDs. While the broad MoA of concomitant AEDs did not influence efficacy or tolerability outcomes, we have provided a framework that may be utilized in future studies to help identify optimal synergistic AED combinations.
Introduction
Thirty-five percent of patients with newly treated epilepsy fail to attain seizure freedom after two or more antiepileptic drugs (AEDs) and are defined as having drug-resistant epilepsy [1, 2] . Despite multiple new AEDs over the last 25 years, rates of drug-resistant epilepsy remain relatively unchanged [1, 3] . In order to move toward the ultimate goal of maximal seizure control with minimal adverse effects, we need to improve our understanding of rational polytherapy. This includes identifying synergism between AEDs and patient risk factor profiles for drug responders and tolerators.
Lacosamide (LCM) is one of the newest AEDs and has been approved in multiple countries as an add-on therapy for focal epilepsy. It has a unique mechanism of action (MoA), which enhances the slow inactivation of voltage gated sodium channels [4, 5] .
Lacosamide has been examined in three randomized controlled trials (RCTs) (n = 1311) [6] [7] [8] ; compared with placebo, LCM was associated with a dose dependent reduction in seizures (50% responder rate of 38-41% on 400 mg LCM compared with 18-26% on placebo) [9] . Three open label extension (OLE) trials (n = 1055) have provided longer-term prospective data which complement the RCTs [10] [11] [12] , but tolerability and efficacy data from OLE can be limited by the variable Epilepsy & Behavior 80 (2018) [25] [26] [27] [28] [29] [30] [31] [32] use of both LCM and concomitant AEDs over such extended follow-up periods.
To help determine the effectiveness and safety of LCM in 'real-world' settings, several retrospective observational studies of LCM have been undertaken [13] [14] [15] [16] [17] . These studies have analyzed moderately sized cohorts (range: n = 106-511) and explored the impact of concomitant AED reduction and the role of sodium channel blocking (SCB) agents in efficacy and safety outcomes. However, there has been limited study of outcomes according to AED combinations and risk factor profiles.
We analyzed the effectiveness and tolerability of adjuvant LCM in a multicenter cohort from three Australian hospitals. In this novel, longterm follow-up study, we aim to identify 'mechanism of action' (MoA) of AED combinations and risk factor profiles which are associated with improved efficacy and tolerability. Using this LCM cohort as an example, we aim to provide a methodological framework for identifying drug synergism, rational polytherapy strategies, and factors predicting response to newer AEDs.
Methods
Participants consecutively commenced on LCM between December 2009 and January 2017 by epilepsy specialists at three Australian hospitals, St Vincent's Hospital Melbourne (SVHM), Royal Prince Alfred Hospital Sydney (RPA), and Royal Perth Hospital (RPH) were identified. Patients were included if they met the following criteria; 16 years or older at time of commencement of LCM, at least one visit following LCM commencement, and a diagnosis of focal epilepsy. Patients were excluded if they had concomitant psychogenic nonepileptic seizures (PNES), less than one seizure in the 12 months prior to commencing LCM, or insufficient available information.
The three Australian hospitals are distinct tertiary institutions with comprehensive epilepsy programs offering video-electroencephalography (EEG) monitoring, invasive EEG, and epilepsy surgery. While the programs are unique, they share a standard framework to clinical care dictated by the national prescribing authority and the common practice in Australia whereby any new compound is typically trialed on patients with treatment-refractory seizures that have not responded to commonly used agents. There was no standardized approach to clinical care across the institutions. However, the fundamental aspects of documentation, diagnosis, and management are regarded to be similar between sites.
Retrospective cohort
Data were collected retrospectively from SVHM and RPA sites. All patients of authors WD and MC from SVHM and AN from RPA who were prescribed LCM were identified from existing databases. A medical chart review was then performed from first consultation to the point at which patients were censored. A subset of cases from SVHM has been included in a previously analysis [14] , however medical charts were re-reviewed for all of these cases.
Prospective cohort
At RPH, data were extracted from an existing prospective seizure outcome database. Patients with drug-resistant epilepsy experiencing at least one disabling seizure per month who were commenced on a new AED including LCM were enrolled and seizure outcome prospectively evaluated.
Lacosamide treatment
Lacosamide initiation varied between institutions and ranged from 50 mg daily for 1-2 weeks to 50 mg twice daily for 4-8 weeks before titration to the usual initial target dose of 100 mg twice daily. The dose was further uptitrated according to efficacy in 50-100 mg increments. Dose down titrations were performed according to tolerability. Patients were reviewed every 3 to 6 months following commencement of LCM.
Data collection
The following baseline variables were collected: gender, intellectual disability, psychiatric diagnosis, age of onset of epilepsy, epileptogenic MRI lesion, previous epilepsy surgery, and previous focal to bilateral tonic-clonic seizures (FBTCS). Age, number of prior AEDs, and the specific AEDs prescribed at time of LCM commencement were also recorded.
Concomitant AEDs were defined on the basis of MoA [18] : SCB (phenytoin, carbamazepine, oxcarbazepine, lamotrigine), gammaaminobutyric acid (GABA) analogues (clonazepam, diazepam, clobazam, phenobarbitone, gabapentin, pregabalin, primidone, tiagabine, vigabatrin), synaptic vesicle protein 2A (SV2A) binding (levetiracetam), and multiple mechanisms (MM) (valproate, topiramate, zonisamide, felbamate). Concomitant AEDs were also separated into categories of 'older agents' (phenytoin, carbamazepine, benzodiazepines, valproate, phenobarbitone, primidone) and 'newer agents' (others). Partial or complete reduction of a concomitant AED following commencement of LCM was recorded.
Two additional measures of the severity of the patient's epilepsy were documented, i) drug-resistant epilepsy, defined as ongoing seizures despite trials of adequate doses of two appropriate AEDs [2] and ii) refractory epilepsy from onset, defined as having never experienced 6 months of seizure freedom from onset of epilepsy to commencement of LCM.
Epilepsies were categorized as focal in accordance with the most recent International League Against Epilepsy (ILAE) classification [19] . Seizure types were classified according to the most recent ILAE operational classification [20] .
Baseline seizure frequency was determined over the 3 months prior to commencement of LCM. This was presented as seizures per month and calculated as 'total seizures over prior three months divided by 3'. If no seizures occurred in the prior 3 months, then the baseline seizure frequency was calculated over the prior 12 months. Baseline seizure frequency was calculated separately for all seizure types and for FBTCS. Baseline seizure frequency was dichotomized into 'low' (below median) and 'high'.
Follow-up
Patients were followed up until the prespecified censor events: i) cessation of LCM, ii) addition or up-titration of another AED, iii) epilepsy surgery, iv) death, or v) end of available follow-up. Total duration of follow-up was defined as date of LCM commencement to the first censor event.
Efficacy outcomes
Efficacy was determined 6 and 12 months following the commencement of LCM. Two efficacy outcomes were assessed at 6 and 12 months i) responder rate and ii) seizure freedom. Responders were defined as those who experienced a greater than 50% reduction in seizure frequency compared with baseline. Seizure frequency on LCM was calculated over the respective 6-and 12-month interval. Seizure freedom was defined as no documented seizures from the baseline time point to assessment time point. Seizure freedom was also quantified at 2, 3, 4 and 5 years after commencement of LCM.
An intention to treat (ITT) approach was undertaken i.e., if they were enrolled in the study and started LCM but did not reach an assessment time point (6 or 12 months), they were included in the analysis as a nonresponder.
The primary outcome of the analysis was the proportion of patients who were responders at 12 months after commencing LCM. Secondary outcomes were seizure freedom at each time point and tolerability endpoints.
Tolerability outcomes
Data on adverse effects were collected over the entire course of follow-up while on LCM. Side effects were categorized a priori, based on the known side effect profile of LCM. Secondary tolerability outcomes were cessation of LCM for any reason, cessation due to sideeffects, or censoring due to inefficacy. Censoring due to inefficacy occurred at the time of addition of a new AED, epilepsy surgery, or cessation of LCM due to inefficacy.
MoA analysis
The relationship between concomitant AEDs according to their MoA (e.g., LCM plus at least SV2A AED) and efficacy and tolerability outcomes were examined. Given that the majority of patients in adjuvant treatment trials and observational studies of newer AEDs are taking at least 2 baseline AEDs, we performed additional MoA analyses to explore the outcomes when LCM was combined with at least two different MoA AEDs, e.g., LCM plus SCB plus SV2A. This approach is adapted from previously reported methodology [18] .
Statistical analysis
Binary efficacy and tolerability outcomes were analyzed using logistic regression. To explore associations, cross-tables of frequencies were examined for each categorical explanatory variable, and summary statistics were examined for each numerical explanatory variable. Each promising variable was fitted on its own in a logistic regression. Those with a P-value less than 0.1 were then entered into a backwards stepwise logistic regression procedure. The final model included only variables significant at the 0.05 level. Time-to-event outcomes were analyzed using Cox regression (proportional hazards). To explore associations, Kaplan-Meier (KM) plots of survival and summary statistics were examined for each categorical explanatory variable, and summary statistics were examined for each numerical explanatory variable. Each promising variable was fitted on its own in a Cox regression. Those with a P-value less than 0.1 were then entered into a backwards stepwise Cox regression procedure. The final model included only variables significant at the 0.05 level. Baseline seizure frequency was log transformed because of its right skewness, and because it predicted the outcomes better than the untransformed variable, OR = odds ratio, HR = hazards ratio, and CI = 95% confidence interval.
Results
Across the three institutions, 484 patients were identified and screened. One hundred seventy-four were excluded, 20 with PNES (concomitant or subsequently), 35 with generalized epilepsy, 6 without seizures in the baseline 12 months, 40 patients who did not actually commence LCM, and 73 cases with insufficient data. The remaining 310 patients meeting inclusion criteria were analyzed and followed up for a median of 17.3 months [interquartile range (IQR): 7.8-37.6 months].
Baseline characteristics for the participants are displayed in Table 1 . The majority of participants had lesional focal epilepsy (60%). One hundred ninety-four patients experienced previous FBTCS, and 86 (28%) patients had at least one FBTCS in the baseline 3 months. The baseline seizure frequency was 4.4 [IQR: 2.0-20.0] seizures per month as calculated over the 3 months prior to commencing LCM. The mean time to commencing LCM from diagnosis was 21 years. Over the entire course of follow-up, the peak daily dose of LCM was b200 mg in 25 cases (8%), 200-299 mg in 77 (25%), 300-399 mg in 62 (20%), and N399 mg in 146 (47%).
Study participant characteristics according to institution are presented in Supplementary Table 1 . Participants from the RPH cohort were younger at diagnosis (P b 0.001) and had a higher proportion, patients who were having refractory epilepsy from onset (P b 0.001). Twenty three percent of SVHM participants had trialed less than 4 AEDs prior to LCM, compared with 9% at RPA, and 2% RPH. Baseline seizure frequency was 2. 
Efficacy
At 6 months following the commencement of LCM, 32% of patients had recorded a 50% or greater reduction in seizure frequency while 11% were seizure-free. At 12 months, these rates fell slightly to 29% and 9%, respectively ( Table 2 ). The 12-month outcomes according to the number of prior AEDs and baseline seizure frequency are presented in Fig. 1 . Of the 244 patients who completed 12 months of follow-up (i.e., 12 month completers), responder, and seizure free rates were 37% and 11%, respectively. Rates of seizure freedom were also calculated for patients with a minimum of 2, 3, 4 and 5 years follow-up following commencement of LCM. One hundred thirty-four patients had 2 years of follow-up following LCM commencement, and 9 (7%) had achieved 2-year seizure freedom; 89 patients were followed to 3 years, with 1 (1%) being seizure-free; 60 and 27 patients had 4 and 5 years of follow-up, respectively, and none of these patients experienced long-term seizure freedom.
Responder and seizure freedom rates differed according to institution. At 6 months, the proportion of responders was 41%, 23%, and 25% (P = 0.009) at SVHM, RPA, and RPH institutions, respectively, while seizure freedom occurred in 16%, 13%, and 3% (P = 0.005), respectively.
The 12-month responder rates were 38%, 20%, and 24% (P = 0.012), respectively, and seizure freedom was experienced in 14%, 8%, and 3% (P = 0.012). Taken together, these seizure outcomes reflect the different baseline characteristics from each institutional cohort.
While there were differences in responder rates between the institutions, this was driven by significant differences in the number of concomitant AEDs (P b 0.001), number of prior AEDs (P b 0.001), and baseline seizure frequency (P b 0.001), i.e., seizure severity. Given these strong associations, the 'institution' variable was removed from the multivariate analysis in preference for these more clinically meaningful explanatory variables.
Predictors of 12-month seizure outcome
The baseline characteristics and concomitant AEDs at LCM initiation were analyzed as explanatory variables for the outcome of being a responder at 12 months (Table 2 Following backwards stepwise logistic regression, the only final variable predictive of a responder was baseline seizure frequency (OR 0.794, CI 0.674-0.936,P = 0.006). For every increase in baseline seizure frequency of 10 seizures per month, the odds of being a 50% responder at 12 months decreases by approximately 20%.
A similar approach was taken to examine the outcome of seizure freedom at 12 months. Following a backwards stepwise logistic regression, three variables remained in the model as predictive of seizure freedom: baseline seizure frequency (OR 0.593, CI 0.430-0.817, P = 0.001), refractory epilepsy from onset (OR 0.252, CI 0.080-0.790, P = 0.018), and the number of concomitant AEDs (OR 0.416, CI 0.248-0.698, P = 0.001). Therefore, a lower baseline seizure frequency, having at least 6 months of seizure freedom from diagnosis and being on fewer concomitant AEDs, was predictive of achieving seizure freedom 12 months after commencing LCM. Taken together, surrogates for less severe refractory epilepsy were predictive of response and seizure freedom at 12 months.
Tolerability
Patients were followed up until the addition of another AED in 69 (22%), cessation of LCM in 101 (33%), epilepsy surgery in 12 (4%), and death in 1 or last clinic appointment in the remaining 127 patients (41%). Two patients who were censored because of epilepsy surgery also had LCM ceased simultaneously. Of those who had LCM ceased, 35 (34.0%) were due to side effects, 62 (60.0%) due to inefficacy, and 6 (6%) due to other reasons.
Side effects were experienced by 138 (44.5%) of patients over the course of follow-up (Supplementary Table 2 ), and 9.7% of patients experienced more than one treatment emergent side effect over the follow-up period. Dizziness was the most common adverse event and was described in 19.4% of patients, this was followed in order of prevalence by sedation (10.3%), blurred or double vision (5.5%), and the development of low mood or anxiety (5.5%). All remaining side effects occurred at a rate of less than 5%. Over the entire follow-up period, a single death occurred; and this was due to suicide in a patient with adolescent onset psychosis.
Predictors of tolerability
The predictors of LCM cessation due to any cause were examined. Following multivariate analysis, two variables were subsequently identified as having an association with LCM cessation: previous FBTCS were linked to longer duration on LCM before cessation (HR 0.62, CI 0.42-0.91, P = 0.015) while increased baseline seizure frequency was predictive of shorter time to cessation (HR 1.16, CI 1.04-1.30, P = 0.009).
Predictors of LCM cessation due to side effects were also analyzed. Antiepileptic drug reduction, with either partial or complete withdrawal of an AED at the time of starting LCM, was associated with a prolonged duration on LCM (OR 0.423, CI 0.192-0.932, P = 0.033). Factors predicting censoring due to inefficacy were explored. This encompassed patients who stopped LCM due to inefficacy or who were censored when another AED was added or when epilepsy surgery occurred. The only predictive variable was the presence of previous FBTCS, which was associated with a prolonged time to censoring (OR 0.699, CI 0.501-0.976, P = 0.035). While previous FBTCS were predictive of LCM tolerability, the occurrence of FBTCS over the baseline 3 months did not influence any tolerability outcomes (P N 0.05).
Kaplan-Meier survival curves were plotted to examine time to cessation (Fig. 2 ). These were analyzed according to whether a concomitant AED was reduced, presence of previous FBTCS, and baseline seizure frequency; these variables were chosen following the above multivariate analyses.
Taken together, these results suggest that reducing concomitant AEDs can limit early LCM cessation because of side effects; that patients with more severe epilepsy stop LCM because of inefficacy rather than side effects; and interestingly, that patients with previous FBTCS tolerate LCM for longer than those without.
MoA -extended analysis
The above efficacy and tolerability analyses have examined the influence of each individual concomitant MoA AED, e.g., LCM plus at least one SCB AED. The following section explores the efficacy and tolerability outcomes when LCM is combined with at least two different MoA AEDs, e.g., LCM plus SCB and GABA analogue (Table 3) .
On univariate analysis, LCM plus SCB plus GABA analogue was associated with lack of response at 6 months (P = 0.029). Of the patients receiving this combination, 24.0% were responders at 6 months compared with 36.4% on different combinations. However, the LCM/SCB/GABA group likely represented a cohort with more severe epilepsy having significantly higher baseline seizure frequency (P b 0.001) who were prescribed a greater number of AEDs prior to LCM (P b 0.001). Finally, post hoc analysis was performed in the 87 patients taking two concomitant AEDs at the time of LCM commencement, both with different MoAs. Twenty patients were taking SCB/SV2A, 14 taking SCB/ GABA, 19 taking SCB/MM, 8 taking SV2A/GABA, 17 taking SV2A/MM, and 9 taking GABA/MM. No significant associations were observed between the MoA combination and efficacy nor tolerability outcomes.
Taken together, no specific 'mechanism of action' drug combinations with LCM offered any consistent efficacy or tolerability advantage.
Discussion
We retrospectively analyzed the long-term effectiveness and tolerability of adjuvant LCM in a cohort of patients with drug-resistant epilepsy across three tertiary Australian hospitals. In this novel analysis, we have explored the role of the nature of the epilepsy and the mechanisms of action (MoA) of concomitant AEDs in predicting outcomes.
The major findings are that i) adjuvant LCM is associated with responder and seizure freedom rates of 29% and 9% respectively at 12 months after commencement; ii) lower seizure frequency prior to LCM initiation predicts being a responder at 12 months; iii) lower prior seizure frequency, at least a 6-month period of seizure freedom from diagnosis and being on fewer concomitant AEDs were predictive of remaining seizure free at 12 months; iv) previous FBTCS, lower baseline seizure frequency, and concomitant AED reduction after LCM commencement were associated with improved LCM tolerability; and v) no specific MoA AED combinations with LCM offered any efficacy or tolerability advantage.
Efficacy
As anticipated, this was a cohort with difficult to control epilepsy. Ninety-seven percent of patients had drug-resistant epilepsy, 45% had never experienced more than 6 months of seizure freedom since diagnosis, and 50% were prescribed more than 7 AEDs before LCM. We utilized a stringent study design that censored patients at addition or up-titration of any concomitant AEDs, incorporated an 'intention-totreat' analysis, and used strict definitions of 50% response and seizure freedom.
Despite the severity of the cohort and strict controlled design, responder rates were 32% and 29% at 6 and 12 months, respectively. These treatment outcomes are comparable to the dose-dependent RCT rates at 12 weeks of 33-41% [6] [7] [8] . Open label extension studies have recorded responder rates of approximately 50% at 12 months [10] [11] [12] , however these allowed flexible dosing of other AEDs and enrolled patients who had already tolerated LCM as part of the RCT. In a large retrospective study of 500 patients, Vilaneueva et al. [16] described 12-month responder rates of 53%. However, the authors utilized a 'last outcome carried forward' approach, allowed flexible dosing of other Table 3 Efficacy and tolerability outcomes according to mechanism of action -univariate analysis. For each concomitant MoA combination, results represent the n (%) with each outcome and the P value of the chi-square or Fisher's Exact Test when that proportion is compared to patients on all other MoA combinations, e.g., of 93 patients taking concomitant SCB + LEV, 26 (28.0%) were responders at 6 months, this rate was not significantly different (P = 0.353) to those taking non-SCB + LEV combinations. AEDS, and 20% of patients had tried 2 or fewer prior AEDs, in contrast to only 8% in the current study. In our study, 12 months of seizure freedom was experienced by 9%, while in those with at least 12 months of follow-up (1 year completer cohort), the rate was 11%. In comparison, seizure freedom was achieved in only 2-3% of those enrolled in LCM RCTs at 12 weeks [6] [7] [8] , and in OLE trials, seizure free rates in the 1 year completer cohorts varied widely from 3 to 24% [10] [11] [12] . In retrospective studies, seizure freedom is experienced by 16%-24% [14, 16, 17] . Taken together, our modest seizure freedom rates are consistent with the severity of epilepsy in our cohort and are within range reported in the drug-resistant epilepsy literature both for LCM and other AEDs [21, 22] .
In our multivariate model, only seizure frequency at LCM initiation was predictive of 12-month responders. Importantly, the number of prior AEDs was not a predictive factor and approximately 25% of patients who were previously prescribed more than 7 AEDs achieved responder status at 12 months. This suggests that LCM can have a meaningful clinical impact in patients who have failed multiple previous AEDs and that seizure frequency may be a useful clinical predictor of likelihood of response.
Tolerability
Forty-four percent of patients experienced treatment emergent side effects, with dizziness being the most common. While these rates were similar to those seen in retrospective cohorts [13, 14, 16, 17] , they were almost half that observed in the RCTs and OLEs, either highlighting one of the limitations of retrospective data collection or the importance of dose adjustment of concomitant AEDs and variable rather than fixed dose initiation schedules [6] [7] [8] [10] [11] [12] . Cessation due to side effects occurred in 11.2% of patients, again at the lower end of that seen in RCTs, OLE, and retrospective studies (9-17%) [16] . Therefore, while treatment emergent side-effects are common, in clinical practice they lead to LCM cessation in only a minority of patients.
In patients who had a concomitant AED reduced or ceased, LCM was tolerated for a longer duration before cessation due to side effects. This is consistent with a retrospective study of 106 patients, which reported that on univariate analysis, planned AED reductions were associated with a reduced likelihood of discontinuation of LCM and side effects [13] . These findings might be viewed as pragmatic applied rational polytherapy. 'Rational polytherapy' remains a theoretical construct with limited evidence on its clinical role and synergism or antagonism of AEDs in epilepsy management [23] .
An interesting observation was the relationship between previous FBTCS and improved tolerability: longer duration before cessation due to any cause and before censoring due to inefficacy. This association was present after controlling for baseline seizure frequency and was not related to the presence of FBTCS in the baseline period. In addition, FBTCS did not predict positive efficacy endpoints. This relationship has not been previously described and requires replication in other cohorts. It may reflect patients with previous FBTCS being more invested in even incremental seizure improvements and more likely to persist with LCM treatment in the presence of mild side effects. Whether patients with previous FBTCS have a specific epilepsy network better suited to LCM requires further study.
MoA of concomitant AEDs
Identifying optimal AED combinations is an essential step toward practicing evidence-based rational polytherapy and understanding AED synergism in a real-world setting [23] . Margolis and colleagues examined combination therapy patterns according to MoA in patients with focal epilepsy [18] . Using administrative claim data, 8615 patients were studied, and authors identified that some MoA combinations (SCB plus SCB, GABA plus GABA) had the shortest persistence and the greatest risk of AED discontinuation. Our current study systematically examines the role of concomitant AEDs according to their MoA with regard to a specific adjunctive AED. We demonstrated that the specific MoA of the concomitant AEDs did not influence LCM effectiveness nor tolerability.
In the setting of LCM, previous research has been focused almost exclusively on the SCB mechanism and limited the analysis to univariate explorations [13, 14, 16, 17] , with some studies further categorizing AEDs as nontraditional SCB, traditional SCB, or non-SCB [13, 17] . With regard to efficacy, Sake and colleagues performed post hoc analyses on pooled phases II and III clinical trial data and found no difference in seizure reduction based upon a concomitant AED with SCB activity [24] . While several retrospective studies have found a greater response in non-SCB cohorts, thorough multivariate analyses were not performed [13, 16, 17] . In terms of tolerability, concomitant SCB agents have been associated with greater rates of side effects [13, 14, 16, 17, 24] , however with regard to the likelihood of discontinuing LCM, results are conflicting and likely reflect the challenges of detecting pure mechanistic effects using overly simplistic MoA categories in patients with complex drug regimens [13, 16] .
Limitations and future directions
The major limitation of this study is the retrospective component to the analysis. However, this is offset to some extent by the prospective arm (RPH Hospital). The 'AED reduction' variable was limited by including patients who underwent either partial or complete concomitant AED reduction over a variable time period, but this reflects clinical practice. As with several previous studies, we recorded 'peak dose reached'. However, this dose was not predetermined, and the final dose reached is influenced by both seizures and tolerability. For this reason, it was removed from the final multivariate models.
While epilepsy surgery, invasive devices and treatment trials should always be readily explored for those with drug-resistant epilepsy, for the majority of such patients, continued trials of previously unutilized AEDs are the most common treatment strategy. In the future, improving efficacy and tolerability outcomes will rely on interrogating large, wellphenotyped prospectively collected datasets. In an era of precision medicine, such datasets can help identify individuals that may benefit most from not just a specific AED, but a specific synergistic drug combination. While the MoA of concomitant AEDs did not influence efficacy or tolerability outcomes in our LCM-treated cohort, we have provided a framework that may be utilized in future studies to help identify optimal synergistic AED combinations.
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